We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
India's Central Drugs Standard Control Organisation (CDSCO) has granted Syntellix the license to bring five different product families of its revolutionary bioabsorbable magnesium-based implants to market.